Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $343.9K in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stetz Gary S. | Director | May 22 '26 | Sale | $3.42 | 87,851 | $300,507 | 146,675 | May 27 06:35 PM |
| Stetz Gary S. | Director | May 26 '26 | Sale | $3.47 | 12,500 | $43,375 | 134,175 | May 27 06:35 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.
Company profile
Tharimmune is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.